Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma

Abstract

Background: The aim of the present study was to evaluate the prognostic significance of B-cell lymphocyte kinase (BLK) expression for survival outcomes in diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP.Methods: We retrospectively analyzed the medical records of 89 patients from two tertiary referral hospitals. The expression of BLK, SYK, and CDK1 were evaluated in a semiquantitative method using an H-score, and the proportions of BCL2 and C-MYC were evaluated.Results: A total of 89 patients received R-CHOP chemotherapy as a first-line chemotherapy. The expression rates of BLK in tumor cells was 39.2% (n = 34). BLK expression status was not significantly associated with clinical variables; however, BLK expression in tumor cells was significantly associated with the expression of both C-MYC and BCL2 (p = .003). With a median follow-up of 60.4 months, patients with BLK expression had significantly lower 5-year progression-free survival (PFS) and overall survival rates (49.8% and 60.9%, respectively) than patients without BLK expression (77.3% and 86.7%, respectively). In multivariate analysis for PFS, BLK positivity was an independent poor prognostic factor (hazard ratio, 2.208; p = .040).Conclusions: Here, we describe the clinicopathological features and survival outcome according to expression of BLK in DLBCL. Approximately 39% of DLBCL patients showed BLK positivity, which was associated as a predictive marker for poor prognosis in patients who received R-CHOP chemotherapy.

Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies

“…Only few studies have, however, investigated longitudinal abundance of (EV-derived) cfRNA markers (87,88). When comparing pre-to interim-, and to posttherapy samples in DLBCL responders, a clear decrease in cell-free mRNA of B-cell related markers was noted, many of which have been proposed as potential diagnostic and/or prognostic biomarkers in DLBCL tissue (89)(90)(91)(92)(93)(94)(95)(96)(97)(98). Moreover, the interim timepoint showed a clear, transient increase in neutrophil-and inflammation-related markers, reflecting an acute-phase reaction during therapy.…”

Mesonephric-like Adenocarcinoma of the Uterine Corpus: Clinicopathological and Prognostic Significance of L1 Cell Adhesion Molecule (L1CAM) Over-expression

“…Tissue sections from the corresponding formalin-fixed, paraffin-embedded blocks were mounted onto SuperFrost Plus Microscope Slides (Thermo Fisher Scientific, Waltham, MA, USA), deparaffinized in xylene, and then rehydrated using an ethanol gradient. Immunohistochemical staining was carried out using a Bond-Max automated immunostainer (Leica Biosystems, Lincolnshire, IL, USA) and a Bond Polymer Refine Detection System (Leica Biosystems), as described previously (11,30,(35)(36)(37)(38)(39). Following antigen retrieval, the slides were incubated with a primary antibody against L1CAM (dilution 1:100, clone EPR18998, Abcam, Waltham, MA, USA).…”